Table 3.
Crude and adjusted HR of any cancer and specific cancers with the combination of bDMARD and MTX compared with bDMARD monotherapya
| Initial treatment | Number of patients | Number of events | Person-years | Rate per 100 person-years | Crude HR | Adjusted HRb (95% CI) |
|---|---|---|---|---|---|---|
| Any cancer | ||||||
| With MTX | 2426 | 176 | 5596 | 3.15 | 0.91 | 1.00 (Reference) |
| No MTX | 61 092 | 4383 | 125 441 | 3.49 | 1.00 | 0.96 (0.82, 1.11) |
| Breast cancer | ||||||
| No MTX | 46 989 | 517 | 97 201 | 0.53 | 1.00 | 1.00 (Reference) |
| With MTX | 1899 | 19 | 4298 | 0.44 | 0.84 | 0.87 (0.55, 1.37) |
| Lung cancer | ||||||
| No MTX | 61 092 | 226 | 125 441 | 0.18 | 1.00 | 1.00 (Reference) |
| With MTX | 2426 | 9 | 5596 | 0.16 | 0.89 | 0.96 (0.49, 1.87) |
| Lymphoma | ||||||
| No MTX | 61 092 | 245 | 125 441 | 0.20 | 1.00 | 1.00 (Reference) |
| With MTX | 2426 | 6 | 5596 | 0.11 | 0.55 | 0.59 (0.26, 1.33) |
| Melanoma | ||||||
| No MTX | 61 092 | 135 | 125 441 | 0.11 | 1.00 | 1.00 (Reference) |
| With MTX | 2426 | 6 | 5596 | 0.11 | 1.00 | 1.11 (0.48, 2.53) |
| NMSC | ||||||
| No MTX | 61 092 | 1894 | 125 441 | 1.51 | 1.00 | 1.00 (Reference) |
| With MTX | 2426 | 68 | 5596 | 1.22 | 0.81 | 0.85 (0.67, 1.09) |
| Any cancer (excluding NMSC) | ||||||
| No MTX | 61 092 | 2512 | 125 441 | 2.00 | 1.00 | 1.00 (Reference) |
| With MTX | 2426 | 108 | 5596 | 1.93 | 0.97 | 1.03 (0.85, 1.25) |
a
Any patient with an outcome event occurring during the first 6 months after the initiation of exposure was not included in the analysis. bAdjusted for deciles of the propensity score and age. bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; CI: confidence interval; NMSC: non-melanoma skin cancer; HR: hazard ratio.